trial · primary record
JAB-23E73
Advanced Solid Tumors
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 344 |
| Primary completion | 2029-02 |
| Primary endpoint | Part A: Number and proportion of patients who experience at least 1 dose-limiting toxicity (DLT) with treatment of JAB-23E73 monotherapy. |
| Registry ID | NCT06973564 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:55.296Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06973564
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.